Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Philip J. Stella"'
Autor:
Saima N. Waqar, David R. Gandara, Vassiliki A. Papadimitrakopoulou, Karen Kelly, Gauri J. Kiefer, Hossein Borghaei, Mary W. Redman, Katherine Minichiello, Roy S. Herbst, Francisco Robert, Philip J. Stella
Publikováno v:
Clin Lung Cancer
Introduction The objective of the Lung-MAP sub-study S1400A was to evaluate the response rate to durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with squamous non–small-cell lung cancer (SqNSCLC). Patients and Methods Pa
Autor:
Peter C. Lucas, Marc J. Gollub, Tracey E. Schefter, Bryan A. Faller, Richard K. Valicenti, Mark A O'Rourke, William Parker, Greg Yothers, Philip J. Stella, Samuel A. Jacobs, Osama E. Rahma, Radhika Kainthla, Thomas J. George, Y. Nancy You, Lisa A. Kachnic, Elin R. Sigurdson, Katherine M. Moxley, Norman Wolmark, Theodore S. Hong, William A. Hall, Namrata Vijayvergia, Linda H. Colangelo, Marcia M. Russell
Publikováno v:
JAMA Oncol
Importance Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations
Autor:
Philip J. Stella, Jerome L Rubin, Joel W. Neal, Ahmed Ali Khalid, Heather A. Wakelee, Ying Huang, Michaela Bowden, David P. Carbone, Suresh S. Ramalingam, Suzanne E. Dahlberg, Gregory J Gerstner, Taofeek K. Owonikoko, Preston D. Steen, Rachel E Lerner, Seena C. Aisner
Publikováno v:
The Lancet Oncology. 17:1661-1671
Summary Background Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets M
Autor:
Jeffrey Crawford, Jeffrey D. Bradley, Katherine Minichiello, Karen Kelly, Philip J. Stella, Vassiliki A. Papadimitrakopoulou, Mark H. Knapp, Mary W. Redman, Corey J. Langer, James L. Wade, Roy S. Herbst, David R. Gandara, Charu Aggarwal, Jieling Miao
Publikováno v:
J Thorac Oncol
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 14, iss 10
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 14, iss 10
Background S1400B is a biomarker-driven Lung-MAP substudy evaluating the phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (sqNSCLC). Methods Eligible patients had tumoral phosp
Autor:
Manmeet Ahluwalia, Helen A. Shih, Amyn M. Rojiani, Shawn Malone, Minesh P. Mehta, Lynn S. Ashby, John B. Fiveash, Maria Werner-Wasik, Minhee Won, Hsiang Hsuan Michael Yu, Philip J. Stella, Volker W. Stieber, Merideth M Wendland, Patrick Y. Wen, Nimish Mohile, Prakash Chinnaiyan, Andrew Y. Kee
Publikováno v:
Neuro-oncology. 20(5)
Background This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblasto
Autor:
Hanna Bandos, Norman Wolmark, Alexander H.G. Paterson, John T. Hamm, Patricia A. Ganz, Luis Baez-Diaz, John W Wilson, Edith A. Perez, Louis Fehrenbacher, Richard G. Margolese, Louise Provencher, Adam Brufsky, Patrick J Ward, Robert L Carolla, Philip J. Stella, Henry R Shibata, Aroop Mangalik, André Robidoux, Johnathan Polikoff
Publikováno v:
Cancer Research. 75:P3-12
Background NSABP B-36 compares 6 cycles of FEC-100 with 4 cycles of standard AC in pts with node-negative breast cancer. As reported separately, no significant differences between the two treatment arms were observed in the primary endpoint of diseas
Autor:
Randolph S. Marks, Philip J. Stella, Andrew V. Grainger, John Wright, Preston D. Steen, Garth D. Nelson, Thanyanan Reungwetwattana, Alex A. Adjei, Nathan R. Foster, Julian R. Molina
Publikováno v:
Lung Cancer. 85:245-250
Introduction To assess the efficacy and the Src-kinase inhibitor saracatinib (AZD-0530) after four cycles of platinum-based chemotherapy for extensive stage small cell lung cancer (SCLC). Methods Patients with at least stable disease received saracat
Autor:
Anas Al-Janadi, Muhammad Usman, J. Paul Monk, Daniel Silbiger, Lance K. Heilbrun, Arif Hussain, Thomas W. Flaig, S. Percy Ivy, Susan Bolton, Primo N. Lara, Philip J. Stella, Daryn Smith, Ulka N. Vaishampayan, Elisabeth I. Heath, Glenn Liu, Philip C. Mack, Heather D. Mannuel, Amado J. Zurita
Publikováno v:
The Oncologist
Lessons Learned The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate cancer (mCRPC). The negative data
Autor:
NJ Karlin, Kendrith M. Rowland, Gamini S. Soori, Philip J. Stella, Alvaro Moreno-Aspitia, H Liu, E. A. Perez, Jake Allred, Howard M. Gross
Publikováno v:
Cancer Research. 72:P1-12
Background: TNBC is characterized by unique molecular profiles, aggressive behavior, poor prognosis and lack of targeted therapies. Brostallicin is a novel synthetic compound from the class of DNA minor groove binding (MGB) anti-cancer agents, making
Autor:
Pankaj Kumar, Jose Castillo, Sachdev P. Thomas, Martin E. Fernandez-Zapico, Shaker R. Dakhil, Daniel Satele, David B. Johnson, Aminah Jatoi, Min Li, Rui Qin, Philip J. Stella
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 24(9)
Because the extant literature suggests wine increases appetite, this study sought to determine whether this effect could be observed in advanced cancer patients with appetite loss. Advanced cancer patients with self-reported loss of appetite were ran